Palvella Therapeutics Inc PVLA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
-
Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
-
Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
-
Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing
-
Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 2026
Trading Information
- Previous Close Price
- $126.39
- Day Range
- $121.34–125.93
- 52-Week Range
- $68.96–161.38
- Bid/Ask
- $124.00 / $126.39
- Shares Outstanding
- 14.41M
- Market Cap
- $1.80B
- Volume/Avg
- 164,224 / 205,213
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 29
- Website
- https://www.palvellatx.com
Valuation
|
Metric
|
PVLA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 8.30 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
PVLA
|
|---|---|
Quick Ratio | 20.97 |
Current Ratio | 21.18 |
Interest Coverage | −7.67 |
Quick Ratio
PVLA
Profitability
|
Metric
|
PVLA
|
|---|---|
Return on Assets (Normalized) | −34.04% |
Return on Equity (Normalized) | −43.33% |
Return on Invested Capital (Normalized) | −39.62% |
Return on Assets
PVLA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|TZ%#%Z | LOCK|>$Y< | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|n@DyK% | LOCK|CMMrG | $83B | |||
| Moderna Inc
MRNA
| LOCK|BrfTsr> | LOCK|K!V | $80B | |||
| argenx SE ADR
ARGX
| LOCK|^q#k%% | LOCK|<< | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|M>!@GFG | LOCK|&K | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|G#r<X$ | LOCK|t%Wx | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|&Fkzc?%J | LOCK|z?bcx | $28B | |||
| Incyte Corp
INCY
| LOCK|#>@c#D! | LOCK|@F | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|Zll&!>F | LOCK|n$ | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|qy$>%vZ | LOCK|q^ | $14B |
United States